title: Hypertension and diabetes: should we treat early surrogates? What are the cons?
authors.affiliation: University Hospital, Malmö, Sweden. peter.nilsson@med.lu.se
authors.forename: Peter M
authors.initials: PM
authors.lastname: Nilsson
mesh_terms: D017311:Amlodipine / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D004359:Drug Therapy, Combination; D017408:Guidelines as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D012307:Risk Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D017311:Amlodipine